Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines

Authors’ contributions
LODS and DB developed the concept of the manuscript. LODS reviewed the 
literature, drafted and wrote the manuscript. DB critically reviewed the manu-
script and provided ideas and comments on the draft. Both authors approved 
the final manuscript.
Acknowledgements
Special thanks to the Formulation Team of the Center for Translational Medi-
cine (CTM) at the University of Montana for their critical review of the manu-
script. Special thanks to Dr. Alyson Smith, CTM’s Immunology Director, for her 
guidance in the immunology-related information discussed in the article.
Competing interests
LODS declares no competing interests. DB is the Chief Operating Officer and 
member of the Board of Directors, Inimmune, Inc. The authors are entirely 
responsible for the content of the review and the opinions contained within it.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This review was written with the support of a NIAID Contract # 
HHSN272201400050C.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 29 August 2017 Accepted: 9 November 2017
References
1. Guy B, Pascal N, Francon A, Bonnin A, Gimenez S, Lafay-Vialon E, 
Trannoy E, Haensler J. Design, characterization and preclinical effi-
cacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine. 
2001;19:1794–805.

---

Page 20 of 23
De Serrano and Burkhart  J Nanobiotechnol (2017) 15:83 
2. Puangpetch A, Anderson R, Huang YY, Sermswan RW, Chaicumpa 
W, Sirisinha S, Wongratanacheewin S. Cationic Liposomes extend the 
immunostimulatory effect of CpG oligodeoxynucleotide against Burk-
holderia pseudomallei infection in BALB/c mice. Clin Vaccine Immunol. 
2012;19:675–83.
3. Capron A, Riveau G, Grzych J-M, Boulanger D, Capron M, Pierce R. 
Development of a vaccine strategy against human and bovine schisto-
somiasis: background and update. Trop Geogr Med. 1994;46:242–6.
4. Girard MP, Fruth U, Kieny MP. A review of vaccine research and develop-
ment: tuberculosis. Vaccine. 2005;23:5725–31.
5. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. 
Liposome-based cationic adjuvant formulations (CAF): past, present, 
and future. J Liposome Res. 2009;19:2–11.
6. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, 
Perrie Y. Liposomes based on dimethyldioctadecylammonium promote 
a depot effect and enhance immunogenicity of soluble antigen. J 
Control Release. 2010;142:180–6.
7. Kallerup RS, Madsen CM, Schioth ML, Franzyk H, Rose F, Christensen D, 
Korsholm KS, Foged C. Influence of trehalose 6,6
ʹ-diester (TDX) chain 
length on the physicochemical and immunopotentiating properties of 
DDA/TDX liposomes. Eur J Pharm Biopharm. 2015;90:80–9.
8. Geijtenbeek TBH, Gringhuis SI. C-type lectin receptors in the control of T 
helper cell differentiation. Nat Rev Immunol. 2016;16:433–48.
9. Goyal S, Klassert TE, Slevogt H. C-type lectin receptors in tuberculosis: 
what we know. Med Microbiol Immunol. 2016;205:513–35.
10. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate 
immune system. Science. 2010;327:291–5.
11. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive 
immunity. Microbes Infect. 2004;6:1382–7.
12. Yao C, Oh JH, Lee DH, Bae JS, Jin CL, Park CH, Chung JH. Toll-like 
receptor family members in skin fibroblasts are functional and have 
a higher expression compared to skin keratinocytes. Int J Mol Med. 
2015;35:1443–50.
13. Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, 
Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm P, et al. 
Human TLR10 is an anti-inflammatory pattern-recognition receptor. 
Proc Natl Acad Sci USA. 2014;111:E4478–84.
14. Cagnoni AJ, Saez JMP, Rabinovich GA, Marino KV. Turning-off signaling 
by siglecs, selectins, and galectins: chemical inhibition of glycan-
dependent interactions in cancer. Front Oncol. 2016;6:21.
15. Dambuza IM, Brown GD. C-type lectins in immunity: recent develop-
ments. Curr Opin Immunol. 2015;32:21–7.
16. Opanasopit P, Higuchi Y, Kawakami S, Yamashita F, Nishikawa M, 
Hashida M. Involvement of serum mannan binding proteins and man-
nose receptors in uptake of mannosylated liposomes by macrophages. 
Biochim Biophys Acta Biomem. 2001;1511:134–45.
17. Kallert S, Zenk SF, Walther P, Grieshober M, Weil T, Stenger S. Liposomal 
delivery of lipoarabinomannan triggers Mycobacterium tuberculosis 
specific T-cells. Tuberculosis. 2015;95:452–62.
18. Hussain MJ, Wilkinson A, Bramwell VW, Christensen D, Perrie Y. Th1 
immune responses can be modulated by varying dimethyldiocta-
decylammonium and distearoyl-sn-glycero-3-phosphocholine content 
in liposomal adjuvants. J Pharm Pharmacol. 2014;66:358–66.
19. Li P, Chen S, Jiang Y, Jiang J, Zhang Z, Sun X. Dendritic cell targeted 
liposomes-protamine-DNA complexes mediated by synthetic manno-
sylated cholestrol as a potential carrier for DNA vaccine. Nanotechnol-
ogy. 2013;24:295101.
20. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes 
as vaccine adjuvants. Expert Rev Vaccines. 2011;10:513–21.
21. McNeil SE, Perrie Y. Gene delivery using cationic liposomes. Expert Opin 
Ther Pat. 2006;16:1371–82.
22. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formula-
tions in clinical use: an updated review. Pharmaceutics. 2017;9:12.
23. Watson DS, Endsley AN, Huang L. Design considerations for liposomal 
vaccines: influence of formulation parameters on antibody and cell-
mediated immune responses to liposome associated antigens. Vaccine. 
2012;30:2256–72.
24. Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing 
liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv 
Rev. 2016;99:85–96.
25. Shahum E, Therien HM. Immunopotentiation of the humoral response 
by liposomes—encapsulation versus covalent linkage. Immunology. 
1988;65:315–7.
26. Shahum E, Therien HM. Liposomal adjuvanticity—effect of encapsula-
tion and surface-linkage on antibody-production and proliferative 
response. Int J Immunopharmacol. 1995;17:9–20.
27. Therien HM, Shahum E. Immunopotentiation of the humoral response 
by liposomes—effect of a T-cell polyclonal activator. Cell Immunol. 
1988;116:320–30.
28. Barnier-Quer C, Elsharkawy A, Romeijn S, Kros A, Jiskoot W. Adjuvant 
effect of cationic liposomes for subunit influenza vaccine: influence of 
antigen loading method, cholesterol and immune modulators. Phar-
maceutics. 2013;5:392–410.
29. Legrue SJ. Carrier and adjuvant properties of liposome-borne tumor-
specific antigens. Cancer Immunol Immunother. 1984;17:135–41.
30. Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB 
liposomal adjuvants plays a role in the cell-mediated immune response 
but has no significant effect on antibody production. J Control Release. 
2011;154:131–7.
31. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Lipid vesicle size 
determines the Th1 or Th2 response to entrapped antigen. J Immunol. 
1998;161:4000–7.
32. Jain S, Indulkar A, Harde H, Agrawal AK. Oral mucosal immuniza-
tion using glucomannosylated bilosomes. J Biomed Nanotechnol. 
2014;10:932–47.
33. Mohammed AR, Bramwell VW, Coombes AG, Perrie Y. Lyophilisation 
and sterilisation of liposomal vaccines to produce stable and sterile 
products. Methods. 2006;40:30–8.
34. Ingvarsson PT, Schmidt ST, Christensen D, Larsen NB, Hinrichs WL, 
Andersen P, Rantanen J, Nielsen HM, Yang M, Foged C. Designing CAF-
adjuvanted dry powder vaccines: spray drying preserves the adjuvant 
activity of CAF01. J Control Release. 2013;167:256–64.
35. Bakowsky H, Richter T, Kneuer C, Hoekstra D, Rothe U, Bendas G, 
Ehrhardt C, Bakowsky U. Adhesion characteristics and stability assess-
ment of lectin-modified liposomes for site-specific drug delivery. 
Biochim Biophys Acta. 2008;1778:242–9.
36. Dunnick JK, Badger RS, Takeda Y, Kriss JP. Vesicle interactions with anti-
body and peptide hormone: role of vesicle composition. J Nucl Med. 
1976;17:1073–6.
37. Perrie Y, Ali H, Kirby DJ, Mohammed AU, McNeil SE, Vangala A. Envi-
ronmental scanning electron microscope imaging of vesicle systems. 
Methods Mol Biol. 2017;1522:131–43.
38. Cohen S, Alonso MJ, Langer R. Novel approaches to controlled-release 
antigen delivery. Int J Technol Assess Health Care. 1994;10:121–30.
39. Chen C, Han D, Cai C, Tang X. An overview of liposome lyophilization 
and its future potential. J Control Release. 2010;142:299–311.
40. Winterhalter M, Lasic DD. Liposome stability and formation: experimen-
tal parameters and theories on the size distribution. Chem Phys Lipids. 
1993;64:35–43.
41. Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential 
immune responses to HIV-1 envelope protein induced by liposomal 
adjuvant formulations containing monophosphoryl lipid A with or 
without QS21. Vaccine. 2015;33:5578–87.
42. Shek PN, Yung BYK, Stanacev NZ. Comparison between multilamellar 
and unilamellar liposomes in enhancing antibody-formation. Immunol-
ogy. 1983;49:37–44.
43. Hampl J, Stepanek J, Franz J, Svoboda I. Incorporation of Bovine